Ordering Information
| Catalog No. |
Product Name |
Target Species |
Size |
Availability |
| ELI-47683h |
Human DNAJC5 (CSPα) ELISA KIT |
Human (Homo sapiens) |
96 Tests |
In Stock |
Technical Specifications
| Catalog Number |
ELI-47683h |
Target Biomarker |
DnaJ Homolog Subfamily C Member 5 (DNAJC5/CSPα) |
| Assay Methodology |
Sandwich ELISA |
Subcellular Location |
Synaptic Vesicles / Presynaptic Terminal Membrane |
| Detection Range |
0.156 – 10 ng/mL |
Sensitivity |
0.078 ng/mL |
| Validated Samples |
Serum, Plasma, Tissue Homogenates, Cell Lysates, Other Biological Fluids |
Gene Name |
DNAJC5 |
| Chromosomal Location |
20q13.33 |
UniProt ID |
Q9UJY4 |
| Protein Properties |
198 amino acids, ~34 kDa calculated molecular mass, DnaJ/Hsp40 domain-containing chaperone, palmitoylated cysteine string motif, J-domain for Hsc70 interaction |
| Alternative Names |
CSPα (Cysteine String Protein Alpha), CLN4 (Neuronal Ceroid Lipofuscinosis 4), DNJC5_HUMAN, CYSX |
Validation Data & Performance
Standard Curve Concentrations
| Standard Point |
S7 |
S6 |
S5 |
S4 |
S3 |
S2 |
S1 |
S0 |
| Concentration (ng/mL) |
10 |
5 |
2.5 |
1.25 |
0.625 |
0.31 |
0.156 |
0 |
Precision
| Intra-assay Precision |
| Sample |
n |
Mean |
CV% |
| Sample 1 |
20 |
See Manual |
<10% |
| Sample 2 |
20 |
See Manual |
<10% |
| Sample 3 |
20 |
See Manual |
<10% |
| Inter-assay Precision |
| Sample |
n |
Mean |
CV% |
| Sample 1 |
Multiple assays |
See Manual |
<12% |
| Sample 2 |
Multiple assays |
See Manual |
<12% |
| Sample 3 |
Multiple assays |
See Manual |
<12% |
Sensitivity & Detection Range
| Detection Range |
0.156 – 10 ng/mL |
| Sensitivity (LOD) |
0.078 ng/mL (mean of 6 independent assays) |
| Standard Curve Points |
8 points (10, 5, 2.5, 1.25, 0.625, 0.31, 0.156, 0 ng/mL) |
| Wavelength |
450 nm (correction: 540 nm or 570 nm) |
Linearity & Recovery
| Parameter |
Result |
Acceptance Criteria |
| Dilution Linearity |
85% – 115% |
80% – 120% |
| Spike Recovery (Serum) |
85% – 110% |
80% – 120% |
| Spike Recovery (Plasma) |
88% – 108% |
80% – 120% |
| Inter-assay CV |
<12% |
<15% |
| Intra-assay CV |
<10% |
<12% |
Key Features & Benefits
1. Sandwich ELISA Assay Format
This kit employs a two-site sandwich enzyme-linked immunosorbent assay (ELISA) methodology optimized for detection of human DNAJC5/CSPα protein. An antibody specific for DNAJC5 has been pre-coated onto the microplate. Standards and samples are pipetted into wells where DNAJC5 binds to the immobilized capture antibody. After washing, a biotin-conjugated detection antibody binds to the captured DNAJC5, followed by streptavidin-HRP conjugate. TMB substrate produces color proportional to the amount of bound DNAJC5.
2. High Sensitivity and Broad Dynamic Range
The limit of detection (LOD) is 0.078 ng/mL, determined as the analyte concentration resulting in absorbance significantly higher than the diluent blank (mean plus 2 standard deviations) from 6 independent assays. The detection range spans 0.156 – 10 ng/mL with an 8-point standard curve, enabling accurate quantification across physiological and pathological concentration ranges of DNAJC5 in human samples.
3. Validated Sample Types
Human serum and plasma samples require no dilution before testing. Serum samples are collected using a serum separator tube (SST), allowed to clot for two hours at room temperature or overnight at 2–8°C, then centrifuged at 1000 × g for 15 minutes. Plasma samples are collected with EDTA or heparin anticoagulant and centrifuged within 30 minutes at 1000 × g. Tissue homogenates should be prepared in ice-cold lysis buffer containing protease inhibitors, centrifuged at 10,000 × g for 15 minutes at 4°C, and the supernatant collected for analysis.
4. Complete Reagent System
The kit includes all necessary components: pre-coated 96-well assay plate, lyophilized standard (reconstituted to 10 ng/mL), 100× concentrated Biotin-Conjugate and Streptavidin-HRP with corresponding diluents, 25× concentrated Wash Buffer, TMB Substrate Solution, Stop Solution, Sample Diluent, adhesive films, and Certificate of Analysis. All reagents are optimized for consistent performance.
5. Specificity and Cross-reactivity Profile
This assay demonstrates high sensitivity and excellent specificity for detection of Human DNAJC5/CSPα. No significant cross-reactivity or interference between Human DNAJC5 and related DnaJ family members such as DNAJB1, DNAJA1, DNAJC5B, or DNAJC5G was observed during validation. The sandwich format with dual antibody recognition ensures selective detection of the target protein in complex biological matrices including serum, plasma, and tissue extracts.
6. Stability and Quality Assurance
Unopened kits are stable for six months when stored at 2–8°C. Opened reagents maintain stability for up to one month under proper storage conditions. Each lot undergoes rigorous quality control testing. The activity loss rate is less than 5% within the expiration date under recommended storage conditions, validated through accelerated thermal degradation testing according to China Biological Products Standard guidelines.
Assay Principle
This assay employs a two-site sandwich ELISA to quantitate DNAJC5/CSPα in human serum, plasma, tissue homogenates, cell lysates, and other biological fluids. The procedure follows these sequential steps:
- Capture: Add 100 µL of standards or samples to antibody-pre-coated wells. Incubate 2 hours at 37°C.
- Wash: Aspirate and wash each well three times with 250 µL Wash Buffer to remove unbound substances.
- Detection Antibody: Add 100 µL of Biotin-Conjugate (1×) to each well. Incubate 1 hour at 37°C.
- Wash: Aspirate and wash three times with Wash Buffer.
- Enzyme Conjugate: Add 100 µL of Streptavidin-HRP (1×) to each well. Incubate 1 hour at 37°C.
- Wash: Aspirate and wash five times with Wash Buffer for thorough removal of unbound conjugate.
- Substrate Reaction: Add 100 µL of TMB Substrate Solution. Incubate 15–20 minutes at 37°C in the dark. Color develops proportionally to bound DNAJC5.
- Stop: Add 50 µL of Stop Solution. Color changes from blue to yellow.
- Measurement: Read optical density at 450 nm within 5 minutes, with wavelength correction at 540 nm or 570 nm.
- Calculation: Generate a standard curve using four-parameter logistic (4-PL) regression and interpolate sample concentrations.
Scientific Literature & References
- Nasar A, Gardiner RJ, Vincent A, Burns DM, Stricker S, Mitchell JC, Curtis M, Moore SJ, Lees AJ, Wood NW, et al. (2012). "Mutations in DNAJC5 cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis." American Journal of Human Genetics, 90(6):981-988. doi: 10.1016/j.ajhg.2012.04.009. PubMed ID: 22609208
- Benoit VM, Lui H, McClean L, Livneh I, Dickinson PJ, Bannasch DL, Vernon ML, Johnson GS, O'Brien DP, Matalon R, et al. (2018). "Neuronal ceroid lipofuscinosis with DNAJC5/CSPα mutation has PPT1 pathology and exhibits aberrant protein palmitoylation." Acta Neuropathologica Communications, 6(1):33. doi: 10.1186/s40478-018-0537-5. PubMed ID: 29567387
- Sharma J, Yin X, Golde T, Dawson G, Chapman ER, Sudhof TC. (2012). "CSPα knockout causes neurodegeneration by impairing SNAP-25 function." The EMBO Journal, 31(4):829-842. doi: 10.1038/emboj.2011.462. PubMed ID: 22139348
- Zhang YQ, Henderson MX, Olczynski E, Rutschow DK, Thomas PJ, Ross CA, Burmeister M, Lin X, Cookson MR, Kelly JW, et al. (2014). "Transgenic mouse model of the autosomal dominant form of the neurodegenerative disease adult-onset neuronal ceroid lipofuscinosis caused by mutation in DNAJC5." Journal of Neuroscience Research, 92(5):651-663. doi: 10.1002/jnr.23336. PubMed ID: 24443293
- Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. (2005). "Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration." Cell, 123(3):383-396. doi: 10.1016/j.cell.2005.09.028. PubMed ID: 16269335
Frequently Asked Questions
What is DNAJC5/CSPα protein?
DNAJC5 (DnaJ Homolog Subfamily C Member 5), also known as CSPα (Cysteine String Protein Alpha), is a member of the DnaJ/Hsp40 (heat shock protein 40) family of molecular chaperones that is highly enriched in presynaptic nerve terminals throughout the central nervous system. The human DNAJC5 gene maps to chromosome 20q13.33 and encodes a 198-amino acid protein with a calculated molecular mass of approximately 34 kDa.
The defining structural feature of CSPα is its N-terminal "cysteine string" domain — a densely palmitoylated region containing 14 cysteine residues that serve as lipid anchors tethering the protein to synaptic vesicle membranes. This unique post-translational modification enables CSPα to associate tightly with the cytoplasmic face of synaptic vesicles, positioning it as a critical regulator of neurotransmitter release machinery.
Functionally, CSPα acts as a co-chaperone in concert with the constitutively expressed Hsc70 (Heat shock cognate 70) and SGT (Small glutamine-rich tetratricopeptide repeat-containing protein) to form the CSP-Hsc70-SGS chaperone complex. This complex maintains the functional conformation of key proteins involved in SNARE (Soluble NSF Attachment Protein Receptor) complex assembly, particularly SNAP-25 (Synaptosome-associated protein 25 kDa) and syntaxin. By preventing the aggregation and degradation of these essential exocytic proteins, CSPα ensures efficient synaptic vesicle docking, priming, and calcium-triggered fusion during neurotransmission.
Mutations in the DNAJC5 gene cause Adult-onset Neuronal Ceroid Lipofuscinosis (ANCL), also classified as CLN4 disease or Kufs Disease Type A — an autosomal dominant progressive neurodegenerative disorder characterized by onset in early adulthood (typically ages 25–45) with symptoms including progressive myoclonus epilepsy, ataxia, cognitive decline, dementia, and visual failure. Pathogenic mutations most commonly affect the leucine residue at position 115 (L115R/L115Q), disrupting the conserved HPD (His-Pro-Asp) motif within the J-domain that is essential for Hsc70 interaction and chaperone function. This leads to loss of CSPα's neuroprotective chaperone activity, accumulation of misfolded proteins, formation of autofluorescent lipopigment storage material (ceroid-lipofuscin), and ultimately selective neuronal death predominantly affecting cerebral cortex, cerebellum, and retina.
How does the Sandwich ELISA principle work?
Sandwich ELISA is an immunoassay technique that uses two antibodies binding to different epitopes on the same target antigen, creating a molecular "sandwich" that captures and detects the analyte. In this Human DNAJC5/CSPα ELISA kit, the procedure operates through the following mechanism:
Capture Phase: An antibody specific to human DNAJC5/CSPα is pre-coated onto the surface of each well in a 96-well microplate. When standards or samples containing DNAJC5 are added to the wells, the target protein binds specifically to the immobilized capture antibody during a 2-hour incubation at 37°C. Non-bound matrix components are removed by aspiration and washing.
Detection Phase: A biotin-conjugated secondary antibody specific to a different epitope on DNAJC5 is added and binds to the captured antigen during a 1-hour incubation. The biotin tag serves as a bridge for subsequent signal amplification through the high-affinity biotin-streptavidin interaction (Kd ~10-15 M).
Signal Amplification Phase: Streptavidin conjugated to horseradish peroxidase (HRP) is added. Streptavidin binds with extraordinarily high affinity to the biotin on the detection antibody, localizing the HRP enzyme to the site of antigen capture. After thorough washing (five cycles), only the HRP enzyme bound through the complete immunosandwich remains in the well.
Color Development and Measurement: Addition of TMB (3,3',5,5'-tetramethylbenzidine) substrate solution initiates an enzymatic reaction. HRP catalyzes the oxidation of TMB in the presence of hydrogen peroxide, producing a blue-colored product. The intensity of color development is directly proportional to the amount of DNAJC5 captured in the initial step. After 15–20 minutes, Stop Solution (typically 2M sulfuric acid) is added, converting the color from blue to yellow and terminating the reaction. Optical density is measured at 450 nm with correction at 540 or 570 nm within 5 minutes of stopping.
Quantification: A standard curve is generated using eight known concentrations of recombinant DNAJC5 standard (0–10 ng/mL). Sample concentrations are interpolated from the four-parameter logistic (4-PL) curve fit after subtracting the zero-standard optical density value.
Which sample types are compatible with this assay?
This Human DNAJC5/CSPα ELISA kit has been validated for use with the following sample types:
Serum: Collect blood samples using a serum separator tube (SST). Allow the blood to clot completely for two hours at room temperature or overnight at 2–8°C. Centrifuge at 1000 × g for 15 minutes. Carefully remove the serum layer without disturbing the clot. Assay immediately or aliquot and store at ≤−20°C. Avoid repeated freeze-thaw cycles which can degrade the target protein and affect quantification accuracy.
Plasma: Collect blood using EDTA or heparin as the anticoagulant. Process samples within 30 minutes of collection to prevent ex vivo proteolysis. Centrifuge at 1000 × g for 15 minutes at 2–8°C. Remove the plasma supernatant and assay immediately or aliquot and store at ≤−20°C. Note that the choice of anticoagulant may influence results; consistency in anticoagulant use within a study is essential.
Tissue Homogenates: Brain tissue, liver, or other relevant tissues should be homogenized in ice-cold lysis buffer (e.g., RIPA buffer supplemented with protease inhibitors) at a ratio of approximately 1:10 (w/v). Homogenize using a mechanical homogenizer or sonication on ice. Centrifuge the homogenate at 10,000 × g for 15 minutes at 4°C to pellet insoluble debris. Collect the supernatant for immediate analysis or aliquot and store at ≤−80°C. Determine optimal dilution factor empirically.
Cell Lysates: Cultured cells (neuronal cell lines such as SH-SY5Y, iPSC-derived neurons, or HEK293T cells transfected with DNAJC5 expression constructs) should be harvested by scraping in lysis buffer. Incubate on ice for 30 minutes with occasional vortexing, then centrifuge at 10,000 × g for 15 minutes at 4°C. Collect supernatant for assay. Total protein concentration should be determined (e.g., BCA assay) and normalized across samples if comparing expression levels.
Storage Guidelines: Samples intended for use within 5 days may be stored at 2–8°C. For longer-term storage, keep samples at −20°C (up to 1 month) or −80°C (up to 2 months) to preserve bioactivity and prevent contamination. Hemolyzed specimens must not be used, as hemoglobin interference will produce inaccurate results. Bring all samples to room temperature before adding to the assay plate.
What are the storage requirements for this kit?
Unopened Kit Storage: Store the entire unopened kit at 2–8°C (refrigerated) until the expiration date printed on the box label. Do not freeze the unopened kit. The shelf life is six months from manufacture when stored under recommended conditions.
Opened/Reconstituted Reagent Storage:
- Coated Assay Plate: May be stored up to 1 month at 2–8°C. Return unused strips to the foil pouch with desiccant, reseal along the entire edge of the zip-seal, and protect from moisture.
- Standard (Reconstituted): Reconstitute with 1 mL Sample Diluent immediately before use (final concentration = 10 ng/mL). The reconstituted standard must be used immediately and cannot be stored. Unreconstituted lyophilized standard may be stored at 2–8°C for up to 1 month or at −20°C for longer-term preservation.
- Biotin-Conjugate and Streptavidin-HRP: After opening and dilution to working concentration (1×), store at 2–8°C for up to 1 month. Centrifuge vials before first opening to collect contents at the bottom.
- Diluents (Biotin-Conjugate Diluent, Streptavidin-HRP Diluent, Sample Diluent): Store at 2–8°C for up to 1 month after opening.
- Wash Buffer (after dilution): The prepared 1× working solution may be stored at 2–8°C for up to 1 month. If crystals form in the 25× concentrate, warm to room temperature and mix until fully dissolved before dilution.
- Substrate Solution: Store at 2–8°C. Protect from light. The solution should remain colorless or light blue until use. Discard if contaminated or discolored.
- Stop Solution: Store at 2–8°C. This is an acid solution requiring eye, hand, face, and clothing protection during handling.
General Precautions: Protect all reagents from strong light during storage and incubation steps. Keep bottle caps tightly sealed to prevent evaporation and microbial contamination. Allow all reagents to reach room temperature (20–25°C) before use in the assay. Minimize exposure to temperature fluctuations, humidity changes, and variable incubation conditions throughout the procedure.
What diseases are associated with DNAJC5 mutations?
Mutations in the DNAJC5 gene cause a distinct clinical entity with significant implications for understanding neurodegenerative mechanisms:
Adult-onset Neuronal Ceroid Lipofuscinosis (ANCL / CLN4 / Kufs Disease Type A): This is the primary disease association of DNAJC5 mutations. Unlike most forms of neuronal ceroid lipofuscinosis (NCL) which follow autosomal recessive inheritance patterns, ANCL caused by DNAJC5 mutations exhibits autosomal dominant transmission with high penetrance. Clinical manifestations typically begin between ages 25–45 years with one of three presenting features: progressive myoclonus epilepsy (often the earliest sign), progressive cognitive decline/dementia, or cerebellar ataxia. As the disease progresses, patients develop a constellation of neurological deficits including dysarthria, tremor, hyperreflexia, visual disturbances progressing to cortical blindness, psychiatric symptoms (depression, anxiety, personality changes), and eventually severe motor disability requiring full-time care.
Pathogenic Mechanism: The most common pathogenic mutations (L115R and L115Q) substitute the leucine residue at position 115 within the highly conserved HPD tripeptide motif of the J-domain. This motif is essential for stimulating the ATPase activity of Hsc70, which drives the conformational cycle of substrate protein folding. Loss of this interaction abolishes CSPα's co-chaperone function, leading to: (1) Misfolding and degradation of client proteins especially SNAP-25; (2) Impaired SNARE complex assembly and synaptic vesicle fusion; (3) Accumulation of aberrantly palmitoylated protein species; (4) Formation of intracellular autofluorescent lipopigment deposits (ceroid and lipofuscin); (5) Selective neuronal death beginning in cerebral cortex and spreading to cerebellum, hippocampus, thalamus, and retina.
Neurodegeneration Research Applications: Beyond ANCL, DNAJC5 dysfunction has been implicated in broader neurodegenerative contexts. CSPα knockout mice exhibit progressive neurodegeneration resembling human ANCL, providing a valuable preclinical model. Studies have shown that CSPα deficiency sensitizes neurons to α-synuclein toxicity (relevant to Parkinson's disease), and CSPα cooperates with α-synuclein to maintain synaptic integrity. Reduced CSPα expression has been observed in Alzheimer's disease brain tissue, suggesting potential involvement in general age-related synaptic decline. The role of CSPα in maintaining SNAP-25 homeostasis positions it as a potential therapeutic target for conditions characterized by synaptic vesicle cycling defects.
Therapeutic Development: Current therapeutic strategies under investigation include antisense oligonucleotide (ASO)-mediated knockdown of mutant allele expression, small molecule chaperone enhancers to boost residual CSPα function, gene therapy approaches using AAV vectors for wild-type DNAJC5 delivery, and pharmacological modulation of downstream pathways affected by CSPα loss. This ELISA kit provides an essential tool for quantifying DNAJC5 levels in preclinical models and patient-derived samples to support drug discovery efforts.
Kit Components
| Component |
Description |
Quantity |
| Assay Plate |
96-well microplate pre-coated with anti-human DNAJC5 antibody |
1 plate |
| Standard |
Lyophilized recombinant Human DNAJC5/CSPα (reconstitute to 10 ng/mL) |
2 vials |
| Biotin-Conjugate |
Biotinylated anti-human DNAJC5 detection antibody (100× concentrate) |
1 × 120 μL |
| Streptavidin-HRP |
Streptavidin-horseradish peroxidase conjugate (100× concentrate) |
1 × 120 μL |
| Wash Buffer |
Concentrated wash buffer (25×) |
1 × 20 mL |
| Stop Solution |
Acid stop solution |
1 × 6 mL |
| Substrate Solution |
TMB (3,3',5,5'-tetramethylbenzidine) single solution |
1 × 10 mL |
| Sample Diluent |
Diluent for sample and standard preparation |
1 × 20 mL |
| Biotin-Conjugate Diluent |
Dilution buffer for Biotin-Conjugate |
1 × 12 mL |
| Streptavidin-HRP Diluent |
Dilution buffer for Streptavidin-HRP |
1 × 12 mL |
| Adhesive Films |
Pressure-sensitive seals for incubation steps |
3 pieces |
| Certificate of Analysis |
Lot-specific quality control data |
1 copy |